Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEMITRANS fecal microbiota transfer for prevention of recurrent urinary tract infections
2025-520452-28-00Phase 2Authorised
- Sponsor
- Goethe University Frankfurt
- Start
- May 2026
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of INTESTIFIX 001, fosfomycin and vancomycin in urinary tract infection (UTI) (2 arms), sponsored by Goethe University Frankfurt. Primary endpoint: Rate of new urinary tract infection episodes within 180 days after treatment. Planned start May 2026; status: authorised.
02
Drugs
INTESTIFIX 001fosfomycinvancomycin
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on 2025-520452-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520452-28-00.